Clinical Trial Search

Primary: Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase — 12.12; 12.29; -5.52; -6.55 Units on a scale — p=0.802

Primary: Time From Randomization to Relapse in the Double-blind (DB) Period — NA; NA days — p=0.0023

Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53

Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02

Primary: Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score — 14.0 score on a scale — p=<0.0001

Primary: Antipsychotic Efficacy — -1.93; -3.76 Score on the NPI-NH scale — p=0.0451

Primary: Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change…

Primary: Patient Evaluation of Symptoms of Psychosis. — -9.8; -12.9; -9.7; -10.0 Scores on a scale — p=0.5177

Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095

Primary: 12-Month Cumulative Incidence of ADRD Diagnoses — 213; 134; 355 Number of new ADRD cases — p=0.006

Primary: Antipsychotic Efficacy — -2.73; -5.79; NA; -3.06 Score on the SAPS-PD scale

Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale

Primary: Treatment-emergent Adverse Events (TEAEs) — 115; 119 Participants

Primary: Change From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6 — -1.4; -2.5 Units on a scale

Primary: Dispensing of Psychotropic Medications — 161; 315 Participants — p=0.492

Primary: Antipsychotic Efficacy — -5.9; -5.8; -6.7; NA Score on the SAPS H+D scale

Primary: Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD) — 35.42; 38.10; 35.56; 36.12 score on a scale

Primary: Number of Participants Who Experienced an Adverse Event — 44; 44 Participants

Primary: Antipsychotic Efficacy — -4.4; NA; -6.5; NA Scores on the SAPS H+D scale

Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score

Primary: Incidence of Hospital Transfers (Patients) — 0.99; 1.12 events per person day at risk — p=0.522

Primary: Role of Essential Oil Therapy in Environmental Diffusion as a Complement of Psychotropic Drugs in the Management of Psychological and Behavioral Disorders (BPSD)…

Primary: Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) — 180 Participants

Primary: Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change — 2.5; 2.43 units on a scale

Primary: Onset of Psychosis — 10; 14 percentage of sample converting

Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015

Primary: Neuropsychiatric Inventory Questionnaire Average Score During Hospital Admission — 5.36; 3.87 score on a scale

Primary: Treatment-emergent Adverse Events (TEAEs) — 238 Participants

Primary: Change in Approaches to Dementia Questionnaire (ADQ) Total Score From Baseline to 3 Months — -1.8; -2.3 units on a scale

Primary: Mean Clinical Global Impression of Change (CGIC) at Last Observation — 2.6; 4.5 units on a scale